FDA Approves ZYN Nicotine Pouches as Safer Alternative to Cigarettes
WHO:
CNN - CEO Jacek Olczak of Philip Morris stated that recent U.S. FDA moves to relax enforcement on unauthorized vaping and nicotine pouches were a “net positive” and would support category growth.
NBC News Health - The Food and Drug Administration (FDA) authorized the maker of ZYN nicotine pouches, Philip Morris, to market the product.
WHAT:
CNN - Philip Morris cut its annual profit forecast for the second time earlier this month.
CNN - The FDA allowed Philip Morris to market 20 variants of ZYN products with the claim that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
CNN - Philip Morris sold 794 million cans of its current version of ZYN in the country in 2025, more than double its 2023 sales.
NBC News Health - The FDA authorized ZYN nicotine pouches to be marketed as safer than cigarettes.
NBC News Health - The change applies to certain flavors of ZYN, including cool mint, citrus, and coffee.
Inc - The FDA’s decision gives Philip Morris a significant advantage in marketing ZYN compared to vapes.
WHERE:
NBC News Health - The FDA is a federal agency based in the United States.
WHEN:
NBC News Health - The FDA announced the decision on a Tuesday.
WHY:
CNN - Tobacco companies have been lobbying U.S. President Trump and other key officials this year for changes they favor, including a faster, clearer FDA authorization process.
NBC News Health - The FDA's decision raises questions about the role of nicotine pouches as a potential successor to vapes.
HOW:
CNN - Nicotine pouches, which users insert under their lip to get a nicotine buzz, are the fastest-growing nicotine product in the U.S., with millions of users.
CNN - The FDA stated that the pouches “would significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole.”
NBC News Health - The FDA's approval allows the marketing of ZYN nicotine pouches with claims of being safer than traditional cigarettes.
(UPDATED July 1, 2026 23:23 UTC)
CEO Jacek Olczak of Philip Morris has described recent moves by the U.S. FDA to relax enforcement on unauthorized vaping and nicotine pouches as a “net positive,” suggesting that these changes will support growth in the category. Earlier this month, Philip Morris cut its annual profit forecast for the second time, highlighting challenges the company is facing. Nicotine pouches, which users place under their lip for a nicotine buzz, are currently the fastest-growing nicotine product in the U.S., boasting millions of users.
--
(UPDATED July 1, 2026 15:52 UTC)
The FDA has granted permission for Philip Morris to market 20 variants of ZYN products, claiming that using ZYN instead of cigarettes lowers the risk of several serious health issues, including mouth cancer and heart disease. In 2025, Philip Morris sold 794 million cans of its current ZYN version, which is more than double the sales from 2023. The FDA believes these pouches will significantly reduce harm and tobacco-related disease risks for individual users and improve overall public health, a decision that comes amid lobbying efforts from tobacco companies seeking changes to the FDA's authorization process.
--
(UPDATED July 1, 2026 04:21 UTC)
The Food and Drug Administration has authorized Philip Morris to market ZYN nicotine pouches, claiming they are safer than traditional cigarettes. This approval applies to specific flavors, including cool mint, citrus, and coffee, and gives Philip Morris a significant edge in the market compared to vapes. The decision raises questions about the potential role of nicotine pouches as a successor to vaping products.